394 related articles for article (PubMed ID: 28492226)
1. Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates.
Kis O; Kaedbey R; Chow S; Danesh A; Dowar M; Li T; Li Z; Liu J; Mansour M; Masih-Khan E; Zhang T; Bratman SV; Oza AM; Kamel-Reid S; Trudel S; Pugh TJ
Nat Commun; 2017 May; 8():15086. PubMed ID: 28492226
[TBL] [Abstract][Full Text] [Related]
2. Construction of a reference material panel for detecting
Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J
J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175
[TBL] [Abstract][Full Text] [Related]
3. Tracking myeloma tumor DNA in peripheral blood.
Waldschmidt JM; Vijaykumar T; Knoechel B; Lohr JG
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101146. PubMed ID: 32139012
[TBL] [Abstract][Full Text] [Related]
4. Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients.
Wang B; Wu S; Huang F; Shen M; Jiang H; Yu Y; Yu Q; Yang Y; Zhao Y; Zhou Y; Pan B; Liu T; Guo W
Clin Chem Lab Med; 2019 Sep; 57(10):1501-1510. PubMed ID: 31339850
[TBL] [Abstract][Full Text] [Related]
5. The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma.
Mishima Y; Paiva B; Shi J; Park J; Manier S; Takagi S; Massoud M; Perilla-Glen A; Aljawai Y; Huynh D; Roccaro AM; Sacco A; Capelletti M; Detappe A; Alignani D; Anderson KC; Munshi NC; Prosper F; Lohr JG; Ha G; Freeman SS; Van Allen EM; Adalsteinsson VA; Michor F; San Miguel JF; Ghobrial IM
Cell Rep; 2017 Apr; 19(1):218-224. PubMed ID: 28380360
[TBL] [Abstract][Full Text] [Related]
6. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
[TBL] [Abstract][Full Text] [Related]
7. Cross-platform comparison of next-generation sequencing and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for detecting KRAS/NRAS/BRAF/PIK3CA mutations in cfDNA from metastatic colorectal cancer patients.
Xu X; Huang F; Cao M; Chen X; Wang H; Jiang H; Yu Y; Shen M; Yang Y; Wang B; Liu T; Guo W
J Clin Lab Anal; 2021 Sep; 35(9):e23818. PubMed ID: 34403504
[TBL] [Abstract][Full Text] [Related]
8. Development and Clinical Validation of Discriminatory Multitarget Digital Droplet PCR Assays for the Detection of Hot Spot KRAS and NRAS Mutations in Cell-Free DNA.
Hussung S; Follo M; Klar RFU; Michalczyk S; Fritsch K; Nollmann F; Hipp J; Duyster J; Scherer F; von Bubnoff N; Boerries M; Wittel U; Fritsch RM
J Mol Diagn; 2020 Jul; 22(7):943-956. PubMed ID: 32376474
[TBL] [Abstract][Full Text] [Related]
9. Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens.
Malapelle U; Mayo-de-Las-Casas C; Molina-Vila MA; Rosell R; Savic S; Bihl M; Bubendorf L; Salto-Tellez M; de Biase D; Tallini G; Hwang DH; Sholl LM; Luthra R; Weynand B; Vander Borght S; Missiaglia E; Bongiovanni M; Stieber D; Vielh P; Schmitt F; Rappa A; Barberis M; Pepe F; Pisapia P; Serra N; Vigliar E; Bellevicine C; Fassan M; Rugge M; de Andrea CE; Lozano MD; Basolo F; Fontanini G; Nikiforov YE; Kamel-Reid S; da Cunha Santos G; Nikiforova MN; Roy-Chowdhuri S; Troncone G;
Cancer Cytopathol; 2017 Aug; 125(8):615-626. PubMed ID: 28475299
[TBL] [Abstract][Full Text] [Related]
10. Major challenges related to tumor biological characteristics in accurate mutation detection of colorectal cancer by next-generation sequencing.
Li W; Qiu T; Guo L; Ying J
Cancer Lett; 2017 Dec; 410():92-99. PubMed ID: 28942013
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy-associated clonal hematopoiesis mutations should be taken seriously in plasma cell-free DNA KRAS/NRAS/BRAF genotyping for metastatic colorectal cancer.
Huang F; Yang Y; Chen X; Jiang H; Wang H; Shen M; Yu Y; Liu T; Pan B; Wang B; Guo W
Clin Biochem; 2021 Jun; 92():46-53. PubMed ID: 33737000
[TBL] [Abstract][Full Text] [Related]
12. Sensitivity, specificity, and accuracy of molecular profiling on circulating cell-free DNA in refractory or relapsed multiple myeloma patients, results of MM-EP1 study.
Quivoron C; Michot JM; Danu A; Lecourt H; Saada V; Saleh K; Vergé V; Cotteret S; Bernard OA; Ribrag V
Leuk Lymphoma; 2024 Jun; 65(6):789-799. PubMed ID: 38433500
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
Palomba G; Doneddu V; Cossu A; Paliogiannis P; Manca A; Casula M; Colombino M; Lanzillo A; Defraia E; Pazzola A; Sanna G; Putzu C; Ortu S; Scartozzi M; Ionta MT; Baldino G; Sarobba G; Capelli F; Sedda T; Virdis L; Barca M; Gramignano G; Budroni M; Tanda F; Palmieri G
J Transl Med; 2016 Oct; 14(1):292. PubMed ID: 27737711
[TBL] [Abstract][Full Text] [Related]
14. Circulating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing.
Chen KZ; Lou F; Yang F; Zhang JB; Ye H; Chen W; Guan T; Zhao MY; Su XX; Shi R; Jones L; Huang XF; Chen SY; Wang J
Sci Rep; 2016 Aug; 6():31985. PubMed ID: 27555497
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of a Liquid Biopsy Protocol using Ultra-Deep Massive Parallel Sequencing for Detecting and Quantifying Circulation Tumor DNA in Colorectal Cancer Patients.
Nguyen HT; Tran DH; Ngo QD; Pham HT; Tran TT; Tran VU; Pham TN; Le TK; Le NT; Nguyen NM; Vo BT; Nguyen LT; Nguyen TV; Bui QTN; Nguyen HN; Luong BA; Le LGH; Do DM; Do TT; Hoang AV; Dinh KT; Phan MD; Tran LS; Giang H; Nguyen HN
Cancer Invest; 2020 Feb; 38(2):85-93. PubMed ID: 31939681
[TBL] [Abstract][Full Text] [Related]
16. Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance.
Módos O; Reis H; Niedworok C; Rübben H; Szendröi A; Szász MA; Tímár J; Baghy K; Kovalszky I; Golabek T; Chlosta P; Okon K; Peyronnet B; Mathieu R; Shariat SF; Hollósi P; Nyirády P; Szarvas T
Oncotarget; 2016 Jun; 7(26):39293-39301. PubMed ID: 27283768
[TBL] [Abstract][Full Text] [Related]
17. Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy.
Seremet T; Planken S; Schreuer M; Jansen Y; Delaunoy M; El Housni H; Lienard D; Del Marmol V; Heimann P; Neyns B
Melanoma Res; 2018 Feb; 28(1):65-70. PubMed ID: 29227333
[TBL] [Abstract][Full Text] [Related]
18. Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab.
Toledo RA; Cubillo A; Vega E; Garralda E; Alvarez R; de la Varga LU; Pascual JR; Sánchez G; Sarno F; Prieto SH; Perea S; Lopéz-Casas PP; López-Ríos F; Hidalgo M
Oncotarget; 2017 May; 8(21):35289-35300. PubMed ID: 27852040
[TBL] [Abstract][Full Text] [Related]
19. Analysis of KRAS, NRAS, PIK3CA, and BRAF mutational profile in poorly differentiated clusters of KRAS-mutated colon cancer.
Reggiani Bonetti L; Barresi V; Bettelli S; Caprera C; Manfredini S; Maiorana A
Hum Pathol; 2017 Apr; 62():91-98. PubMed ID: 28025078
[TBL] [Abstract][Full Text] [Related]
20. Detection of tumor-derived cell-free DNA from colorectal cancer peritoneal metastases in plasma and peritoneal fluid.
Van't Erve I; Rovers KP; Constantinides A; Bolhuis K; Wassenaar EC; Lurvink RJ; Huysentruyt CJ; Snaebjornsson P; Boerma D; van den Broek D; Buffart TE; Lahaye MJ; Aalbers AG; Kok NF; Meijer GA; Punt CJ; Kranenburg O; de Hingh IH; Fijneman RJ
J Pathol Clin Res; 2021 May; 7(3):203-208. PubMed ID: 33635598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
